Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase II, Open-Label, Multicenter Study With a Safety Run-In to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of MT027 Administrated Intracerebroventricularly in Patients With Recurrent or Progressive Glioblastoma (WHO Grade 4)

This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurr…

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Estimated

~$10 – $8,750

T-MAXIMUM Pharmaceutical IncNCT07386002

Phase 1

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatme…

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more

Estimated

~$10 – $5,625

National Institute of Neurological Disorders and Stroke (NINDS)NCT07416188

Phase 1

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide …

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III

Estimated

~$10 – $7,500

Debiopharm International SANCT05765812

Phase 2

A Randomized Phase II Study of the Efficacy of Laser Interstitial Thermal Therapy (LiTT) Combined With Cemiplimab Versus Physician's Choice Chemotherapy in Recurrent Glioblastomas

This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therap…

GlioblastomaGlioblastoma, IDH-wildtypeGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07620548

Phase 1

An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astro…

Glioblastoma, IDH-wildtypeGlioblastomaGlioblastoma Multiforme+4 more

Estimated

~$10 – $8,750

Orbus Therapeutics, Inc.NCT05879367